Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

Drug Research

Volumn 66, Issue 2, 2015, Pages 107-112

  Jain, M R ^a   Joharapurkar, A A ^a   Pandya, V ^a   Patel, V ^a   Joshi, J ^a   Kshirsagar, S ^a   Patel, K ^a   Patel, P R ^a   Desai, R C ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

chemotherapy; CKD; hepcidin; HIF; novel drug

Indexed keywords

CISPLATIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROLYL HYDROXYLASE INHIBITOR; UNCLASSIFIED DRUG; ZYAN 1; ERYTHROPOIETIN; HEPCIDIN; HIF1A PROTEIN, RAT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE COUNT; EXPERIMENTAL ANEMIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; RAT; RETICULOCYTE COUNT; WISTAR RAT; ANEMIA; ANIMAL; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; LIVER; METABOLISM;

ANEMIA; ANIMALS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE COUNT; ERYTHROPOIETIN; HEMOGLOBINS; HEPCIDINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; LIVER; MALE; MICE; NEPHRECTOMY; PROLYL-HYDROXYLASE INHIBITORS; RATS; RATS, WISTAR;

EID: 84957944605     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0035-1554630     Document Type: Article

References (23)

1. McLean E., Cogswell M., Egli I. et al. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr: 2009; 12 444 454
2. Campbell K. Anaemia: causes and treatment. Nurs Times: 2003; 99 30 33
3. Melosky B. L. Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol: 2008; 15 S10 S15
4. Melnikova I. Anaemia therapies. Nat Rev Drug Discov: 2006; 5 627 628
5. Muchnik E., Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs: 2011; 20 645 656
6. Hare G. M., Tsui A. K., Ozawa S. et al. Anaemia: can we define haemoglobin thresholds for impaired oxygen homeostasis and suggest new strategies for treatment? Best Pract Res Clin Anaesthesiol: 2013; 27 85 98
7. Lando D., Gorman J. J., Whitelaw M. L. et al. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem.: 2003; 270 781 790
8. Jaakkola P., Mole D. R., Tian Y. M. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science: 2001; 292 468 472
9. Semenza G. L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol: 2000; 88 1474 1480
10. Smith T. G., Talbot N. P. Prolyl hydroxylases and therapeutics. Antioxid Redox Signal: 2010; 12 431 433
11. Peyssonnaux C., Zinkernagel A. S., Schuepbach R. A. et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest: 2007; 117 1926 1932
12. Virgilli-Lopez G. Roxadustat. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, treatment of anemia. Drugs of the Future: 2014; 39 783 791
13. Denny W. A. Giving anemia a boost with inhibitors of prolyl hydroxylase. J Med Chem.: 2012; 55 2943 2944
14. Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet: 2009; 373 1532 1542
15. Minamishima Y. A., Kaelin W. G. Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science: 2010; 329 407
16. Bellizzi V., Sabbatini M., Fuiano G. et al. The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol Dial Transplant: 1998; 13 2210 2215
17. Weidemann A., Johnson R. S. Nonrenal regulation of EPO synthesis. Kidney Int: 2009; 75 682 688
18. Flamme I., Oehme F., Ellinghaus P. et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One: 2014; 9 e111838
19. Bernhardt W. M., Wiesener M. S., Scigalla P. et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol: 2010; 21 2151 2156
20. Wood P. A., Hrushesky W. J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest: 1995; 95 1650 1659
21. Bokemeyer C., Oechsle K., Hartmann J. T. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Invest: 2005; 35 03 26 31
22. Dufour P., Bergerat J. P., Eber M. et al. Cisplatin-induced anemia: a potential interference with iron metabolism at erythroid progenitors level. Anticancer Drugs: 1990; 1 49 54
23. Gafter-Gvili A., Rozen-Zvi B., Vidal L. et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol: 2013; 52 18 29